Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) gapped down prior to trading on Thursday . The stock had previously closed at $52.02, but opened at $46.01. Supernus Pharmaceuticals shares last traded at $40.54, with a volume of 2278384 shares.
Several brokerages have recently issued reports on SUPN. Cantor Fitzgerald restated a “buy” rating and set a $56.00 target price on shares of Supernus Pharmaceuticals in a research report on Friday, September 14th. Mizuho began coverage on shares of Supernus Pharmaceuticals in a research report on Monday, September 17th. They set a “buy” rating and a $61.00 target price on the stock. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, October 30th. Cowen set a $55.00 target price on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, November 30th. Finally, B. Riley decreased their target price on shares of Supernus Pharmaceuticals from $68.00 to $65.00 and set a “buy” rating on the stock in a research report on Monday, November 12th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $56.89.
The company has a current ratio of 2.82, a quick ratio of 2.65 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of 30.41, a PEG ratio of 1.45 and a beta of 0.93.
A number of institutional investors have recently bought and sold shares of SUPN. Glenmede Trust Co. NA grew its stake in Supernus Pharmaceuticals by 3.2% in the 2nd quarter. Glenmede Trust Co. NA now owns 652,806 shares of the specialty pharmaceutical company’s stock worth $39,070,000 after acquiring an additional 20,012 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in Supernus Pharmaceuticals by 28.1% in the 3rd quarter. Janney Montgomery Scott LLC now owns 13,860 shares of the specialty pharmaceutical company’s stock worth $698,000 after acquiring an additional 3,039 shares in the last quarter. Icon Advisers Inc. Co. bought a new position in Supernus Pharmaceuticals in the 3rd quarter worth about $3,877,000. Oppenheimer Asset Management Inc. grew its stake in Supernus Pharmaceuticals by 9.2% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 14,813 shares of the specialty pharmaceutical company’s stock worth $746,000 after acquiring an additional 1,251 shares in the last quarter. Finally, Cynosure Advisors LLC grew its stake in Supernus Pharmaceuticals by 55.0% in the 2nd quarter. Cynosure Advisors LLC now owns 8,260 shares of the specialty pharmaceutical company’s stock worth $494,000 after acquiring an additional 2,930 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Supernus Pharmaceuticals (SUPN) Shares Gap Down to $46.01” was published by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2018/12/07/supernus-pharmaceuticals-supn-shares-gap-down-to-46-01.html.
About Supernus Pharmaceuticals (NASDAQ:SUPN)
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
See Also: What is Net Asset Value (NAV)?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.